Berger Dietmar 4

What Happened
Dietmar Berger, Chief Medical Officer of Gilead Sciences (GILD), received an award of 8,530 shares on 2026-02-27. The shares were reported as acquired at $0.00 (award/vested performance shares), so no cash was paid. This transaction reflects a compensation-related award rather than an open-market buy or sale.

Key Details

• Transaction date: 2026-02-27; Form 4 filed 2026-03-02.
• Transaction type/code: Award/Acquisition (A).
• Shares acquired: 8,530; reported acquisition price: $0.00; reported total cash value: $0.
• Shares owned after transaction: Not specified in the summarized data (see official filing for post-transaction holdings).
• Footnote: These shares are tranches of performance share awards granted March 10, 2025; they were subject to performance-vesting and service-vesting, and the performance-vesting requirement was certified as satisfied on the reported date by the Compensation and Talent Committee.
• Filing timeliness: Form 4 filed on 2026-03-02 for a 2026-02-27 transaction; check the official filing for any late-filing flag.

Context
Performance-share awards are a form of compensation that vest when preset performance and service conditions are met; they are not purchases or sales and therefore do not by themselves indicate the insider buying or selling stock in the market. For full details (post-transaction holdings, tax withholdings, or any additional footnotes), consult the complete SEC Form 4 filing (Accession: 0001739515-26-000004).